ACTIVITY DESCRIPTION
In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will:
-
Review guideline recommendations for biomarker testing and treatment selection
-
Present clinical evidence for the use of current and emerging targeted therapies
-
Discuss health disparities in biomarker testing
Speakers
Sanjay K. Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line
Chief of Oncology Line
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Dr. Sanjay Juneja is a triple board certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, and a social & news media personality known as 'TheOncDoc' with over half a million followers. He is an active participant for the White House Healthcare Leaders in Social Media Roundtable and national speaker. Dr. Juneja is the host of an innovative podcast called 'Target: Cancer' with distinguished academicians and celebrities around the country, and been featured in several articles including The Washington Post and guested on dozens of acclaimed podcasts and regional news channels (PBS, CBS, NBC, NPR). He is a Business Report's 40 under 40 recipient from his hometown of Baton Rouge, where he partners with the LA Department of Health and Mayor's office to optimize healthcare access and outreach. Dr. Juneja currently practices in his beloved hometown of Baton Rouge Louisiana with his wife Dr. Lauren and their three wild boys.
Narjust Florez, MD
Associate Director of The Cancer Care Equity Program
Thoracic Oncologist – Lowe Center For Thoracic Oncology
Dana-Farber Cancer Institute
Thoracic Oncologist – Lowe Center For Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Narjust Florez, MD is originally from Venezuela. She completed her internal medicine residency at Rutgers New Jersey Medical School and fellowship at the Mayo Clinic in Rochester, Minnesota, where she was the chief fellow from 2018 -2019.
She is the Associate Director of the Cancer Care Equity Program, a thoracic medical oncologist at the Dana-Farber Cancer Institute/Harvard Cancer Center and a Member of the Faculty at Harvard Medical School. In 2022, Dr. Florez also became the first Latina to hold an Associate Editor position in oncology as the new Associate Editor for Diversity, Equity and Inclusion at the JAMA Oncology Journal.
Dr. Florez’s clinical interests include targeted therapy for lung cancer and the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.
Apart from her clinical interests in lung cancer, she is also a leading and productive researcher in cancer health disparities, gender and racial discrimination in medical education and medicine. Dr. Florez is one of the co-founders of the Twitter community #LatinasInMedicine, now composed of over 8,500 members globally. She received many awards, including the 2018 Resident of the Year Award by the National Hispanic Medical Association, 2019 the Mayo Brothers Distinguished Fellowship award, the 2020 Rising Star award by the LEAD national conference for women in hematology and oncology, and the 2021 International Association for the Study of Lung Cancer (IASLC) North America Cancer Care Team Award for outstanding clinical care.
In addition, Dr. Florez founded the Florez (formerly Duma) Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine and medical education. The laboratory long-term goals are to create a welcoming environment for medical trainees from historically underrepresented groups in medicine while improving the care of vulnerable populations. Members of the Florez Lab are agents of change. Since its foundation, the Duma laboratory has received research funding from several national agencies, published over 30 studies and editorials.
Her work has been published in journals such as the Journal of Clinical Oncology, Nature, Cancer Cell, JAMA Oncology, Lancet Oncology, Journal of the National Cancer Institute, (amongst many others), and featured in various media outlets including The New York Times, STAT News, Healio, Onclive, Vox News, Business Insider, ASCO Post, and Doximity.
Lauren Ritterhouse, MD, PhD
Associate Director, Center for Integrated Diagnostics
Assistant Professor, Harvard Medical School
Assistant Pathologist, Massachusetts General Hospital
Boston, MA
Lauren Ritterhouse, MD, PhD, specializes in diagnostic molecular genetic pathology with expertise in biomarkers for personalized medicine in cancer. She is a member of the Center for Integrated Diagnostics (CID) at Massachusetts General Hospital.
Dr. Ritterhouse joined the Massachusetts General Hospital Department of Pathology and Center for Integrated Diagnostics as a staff pathologist in 2019. Prior to this, she was the Co-Director of the clinical genomics and molecular diagnostic laboratories at the University of Chicago. She received her MD, PhD from the University of Oklahoma where she studied the pathogenic roles of aberrant cytokine production in autoimmunity. She completed a Molecular Genetic Pathology Fellowship at Harvard Medical School and Anatomic Pathology Residency at Brigham and Women’s Hospital in Boston, MA. She is particularly interested in the translation of emerging molecular biomarkers into the clinical laboratory, including those evaluating response to immunotherapy, solid tumor mutational signature profiling, circulating tumor DNA, as well as hematologic malignancies.
Accreditation and Disclosure Information
TARGET AUDIENCE
This CE activity is intended for community-based oncology clinicians including physicians, advanced practice providers (APPs, ie, NPs and PAs), nurses, and pharmacists who provide care for individuals with NSCLC.
This CE activity is intended for community-based oncology clinicians including physicians, advanced practice providers (APPs, ie, NPs and PAs), nurses, and pharmacists who provide care for individuals with NSCLC.
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
After completing this CE activity, the participant should be better able to:
-
Evaluate the clinical implications of guideline recommendations for biomarker testing
-
Assess the pros and cons of DNA-based next-generation sequencing (NGS), RNA-based NGS, and liquid biopsy
-
Plan strategies to address disparities in the application of biomarker testing
-
Use results of biomarker tests to select and predict results of therapy for patients with and without targetable driver mutations
ACCREDITATION, SUPPORT AND CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hours and 0.16 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
Medical Learning Institute, Inc. designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-120-H01-P
Type of Activity: Knowledge
Type of Activity: Knowledge
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until March 31, 2023. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
SUPPORT STATMENT
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, and Sanofi.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Sanjay Juneja ,MD
Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Chief of Oncology Line
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Advisory Board/Consultant for Daiichi Sankyo and Guardant 360.
Speakers’ Bureau with AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc. and Tempus.
Stock Ownership with Phenomune and xCures.
Independent Contractor for xCures.
Planner/Presenter
Lauren Ritterhouse, MD, PhD
Associate Director, Center for Integrated Diagnostics
Assistant Professor, Harvard Medical School
Assistant Pathologist, Massachusetts General Hospital
Boston, MA
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Amgen, AstraZeneca, EMD Serono, Merck, Sanofi Genzyme
Planner/Presenter
Narjust Florez, MD
Associate Director of The Cancer Care Equity Program
Thoracic Oncologist – Lowe Center For Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Boston, MA
Advisory Board/Consultant: AstraZeneca, Bristol Myers Squibb/Novartis, Daiichi Sankyo, NeoGenomics, Pfizer
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Merck, Mirati
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.